Key Points
- Disc Medicine COO Jonathan Yen-Wen Yu sold 804 shares at an average price of $82.64, generating $66,442.56. He retained 54,324 shares, and the sale reduced his ownership by 1.46%.
- Yu has made several additional sales since June, including 18,612 shares in June and 9,700 shares later that month, bringing the disclosed recent sales to more than 29,000 shares.
- Disc Medicine shares opened at $78.84, while analysts maintain a “Moderate Buy” consensus with an average price target of $106.00; institutional investors own 83.70% of the company.
Disc Medicine, Inc. (NASDAQ:IRON - Get Free Report) COO Jonathan Yen-Wen Yu sold 804 shares of Disc Medicine stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $82.64, for a total value of $66,442.56. Following the transaction, the chief operating officer owned 54,324 shares in the company, valued at approximately $4,489,335.36. This trade represents a 1.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Jonathan Yen-Wen Yu also recently made the following trade(s):
- On Tuesday, July 7th, Jonathan Yen-Wen Yu sold 100 shares of Disc Medicine stock. The stock was sold at an average price of $82.50, for a total value of $8,250.00.
- On Friday, June 26th, Jonathan Yen-Wen Yu sold 300 shares of Disc Medicine stock. The shares were sold at an average price of $72.50, for a total value of $21,750.00.
- On Monday, June 22nd, Jonathan Yen-Wen Yu sold 9,700 shares of Disc Medicine stock. The shares were sold at an average price of $72.66, for a total value of $704,802.00.
- On Tuesday, June 16th, Jonathan Yen-Wen Yu sold 18,612 shares of Disc Medicine stock. The shares were sold at an average price of $69.19, for a total value of $1,287,764.28.
Disc Medicine Price Performance
NASDAQ:IRON opened at $78.84 on Friday. The company has a quick ratio of 24.14, a current ratio of 24.14 and a debt-to-equity ratio of 0.09. The business's 50-day moving average price is $74.60 and its 200 day moving average price is $69.96. Disc Medicine, Inc. has a 52-week low of $40.00 and a 52-week high of $99.50. The firm has a market cap of $301.96 million, a P/E ratio of -11.98 and a beta of 1.00.
Disc Medicine (NASDAQ:IRON - Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The company reported ($1.54) earnings per share for the quarter, beating analysts' consensus estimates of ($1.71) by $0.17. As a group, sell-side analysts predict that Disc Medicine, Inc. will post -6.61 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
IRON has been the subject of several recent research reports. Morgan Stanley increased their target price on shares of Disc Medicine from $80.00 to $85.00 and gave the company an "overweight" rating in a research note on Monday, June 15th. HC Wainwright upped their price target on Disc Medicine from $118.00 to $120.00 and gave the company a "buy" rating in a report on Thursday, August 6th. Wall Street Zen upgraded Disc Medicine from a "sell" rating to a "hold" rating in a research report on Saturday, August 1st. Weiss Ratings reissued a "sell (d-)" rating on shares of Disc Medicine in a research note on Friday, July 17th. Finally, Wedbush restated an "outperform" rating and issued a $88.00 target price on shares of Disc Medicine in a report on Wednesday, June 10th. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $106.00.
Get Our Latest Stock Report on IRON
Institutional Investors Weigh In On Disc Medicine
A number of large investors have recently made changes to their positions in IRON. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Disc Medicine by 22.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,138 shares of the company's stock worth $756,000 after purchasing an additional 2,807 shares during the period. Millennium Management LLC raised its stake in Disc Medicine by 1,277.1% during the 1st quarter. Millennium Management LLC now owns 108,499 shares of the company's stock valued at $5,386,000 after purchasing an additional 100,620 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Disc Medicine by 3.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 96,557 shares of the company's stock valued at $4,793,000 after purchasing an additional 3,454 shares in the last quarter. Legal & General Group Plc lifted its holdings in shares of Disc Medicine by 18.0% in the second quarter. Legal & General Group Plc now owns 24,097 shares of the company's stock valued at $1,276,000 after purchasing an additional 3,682 shares in the last quarter. Finally, Invesco Ltd. boosted its position in shares of Disc Medicine by 21.6% in the second quarter. Invesco Ltd. now owns 16,817 shares of the company's stock worth $891,000 after buying an additional 2,983 shares during the period. Institutional investors and hedge funds own 83.70% of the company's stock.
Disc Medicine Company Profile
(
Get Free Report)
Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.
The company's pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
